Handelsavisen has updated its investment thesis for Pacific Biosciences of California Inc (PACB.O) following an internal data audit.
The revision stems from a sector classification correction that prompted a re-analysis of the company’s positioning within the broader biotechnology landscape.
The adjustment was triggered by a sector-fix batch process that identified contamination in the previous GICS-direct path mapping.
This technical correction required Handelsavisen’s research systems to re-evaluate the firm’s sector alignment and associated risk metrics.
The updated analysis maintains a composite score of 37.44 out of 100, reflecting persistent concerns regarding the company’s financial health and market position.
Handelsavisen’s internal assessment continues to flag negative net cash after debt as a significant liquidity risk, suggesting that the firm remains vulnerable to broader market volatility and funding constraints.